Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 694

Results For "IP"

10402 News Found

Strong order book in CMO segments for J.B. Chemicals & Pharmaceuticals, says Prabhudas Lilladher
News | November 15, 2022

Strong order book in CMO segments for J.B. Chemicals & Pharmaceuticals, says Prabhudas Lilladher

The company sees the business reaching $100mn


Nikon India forays into the Indian healthcare sector
News | November 15, 2022

Nikon India forays into the Indian healthcare sector

Nikon’s newly launched product AXR Point scanning confocal microscope provides “World’s largest Field of View” of 25mm in one single shot


Lynparza in combination with Abiraterone and prednisone receives positive opinion from EU CHMP
Drug Approval | November 15, 2022

Lynparza in combination with Abiraterone and prednisone receives positive opinion from EU CHMP

First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations


Chemcon Q2 FY23 revenue down 5.4%; Profit down 46.6%
News | November 14, 2022

Chemcon Q2 FY23 revenue down 5.4%; Profit down 46.6%

Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers


GL Chemtech appoints Dr. John Warner as Green Chemistry Innovation Advisor
People | November 14, 2022

GL Chemtech appoints Dr. John Warner as Green Chemistry Innovation Advisor

Reinforcing GLC’s commitment to sustainable processing in pharmaceutical chemistry


Suven Life Sciences posts Q2FY23 consolidated loss at Rs. 23.18 Cr
News | November 14, 2022

Suven Life Sciences posts Q2FY23 consolidated loss at Rs. 23.18 Cr

The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022


GSK India announces 9% sales growth across General Medicines and Specialty business
News | November 14, 2022

GSK India announces 9% sales growth across General Medicines and Specialty business

The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth


Aurobindo Pharma Q2 FY23 revenue down 3.4%
News | November 14, 2022

Aurobindo Pharma Q2 FY23 revenue down 3.4%

Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore


Alembic receives USFDA final approval for Cyclophosphamide Capsules
Drug Approval | November 14, 2022

Alembic receives USFDA final approval for Cyclophosphamide Capsules

Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.


Stelis receives recommendation from EMA granting market authorization for Kauliv
Drug Approval | November 14, 2022

Stelis receives recommendation from EMA granting market authorization for Kauliv

Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.